Patents by Inventor Pablo Umana

Pablo Umana has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunoconjugates
    Patent number: 10316104
    Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: June 11, 2019
    Assignee: ROCHE GLYCART AG
    Inventors: Oliver Ast, Peter Bruenker, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana
  • REMOVAL OF CANCER CELLS BY CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING CANCER CELL TARGETED MHC CLASS 1 COMPROMISING MULTI-FUNCTION PROTEINS
    Publication number: 20190169309
    Abstract: Herein is reported a multi-function protein, characterized in that it comprises exactly one antigen presenting domain, exactly one antibody Fc-region, and at least one antigen binding site, wherein the antigen presenting domain comprises in N- to C-terminal direction either (i) a ?2-microglobulin, and (ii) the extracellular domains ?1, ?2, and ?3 of a class I MHC molecule with a relative frequency of less than 1%, or (i) a T-cell response eliciting peptide, (ii) a ?2-microglobulin, and (iii) the extracellular domains ?1, ?2, and ?3 of a class I MHC molecule with a relative frequency of 1% or more, wherein the antigen binding site binds to a cancer cell surface antigen.
    Type: Application
    Filed: July 30, 2018
    Publication date: June 6, 2019
    Applicant: Roche Glycart AG
    Inventors: Christian Klein, Hendrik Knoetgen, Martina Schmittnaegel, Pablo Umana
  • MODIFIED ANTI-TENASCIN ANTIBODIES AND METHODS OF USE
    Publication number: 20190169277
    Abstract: The present invention relates to improved antibodies specific for Tenascin-C (TnC), in particular domain specific anti-TnC antibodies with improved cross-species reactivity. In addition, the invention relates to polynuleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies and methods of using them in the treatment of disease.
    Type: Application
    Filed: November 9, 2018
    Publication date: June 6, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ralf HOSSE, Ekkehard MOESSNER, Pablo UMANA
  • Bispecific antibodies specific for PD1 and TIM3
    Patent number: 10287352
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: May 14, 2019
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Laura Codarri-Deak, Georg Fertig, Jens Fischer, Christian Klein, Viktor Levitski, Valeria Lifke, Mario Perro, Joerg Thomas Regula, Tilman Schlothauer, Stefan Seeber, Pablo Umana, Ildiko Wuensche, Adrian Zwick
  • PROTEASE-ACTIVATED T CELL BISPECIFIC MOLECULES
    Publication number: 20190119383
    Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
    Type: Application
    Filed: September 21, 2018
    Publication date: April 25, 2019
    Inventors: Peter BRUENKER, Rebecca CROASDALE-WOOD, Christian KLEIN, Juergen Michael SCHANZER, Kay-Gunnar STUBENRAUCH, Pablo UMANA, Martina GEIGER, Eric SULLIVAN, Jigar PATEL
  • Antigen Binding Molecules That Bind EGFR, Vectors Encoding Same, and Uses Thereof
    Publication number: 20190106497
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Application
    Filed: April 27, 2018
    Publication date: April 11, 2019
    Inventors: Pablo Umaña, Ekkehard MÖSSNER
  • Bispecific antibodies against CD3? and BCMA
    Patent number: 10253104
    Abstract: A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3?, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to EU index of Kabat). Also the manufacture and use of said antibody.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: April 9, 2019
    Assignee: ENGMAB AG
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Lydia Jasmin Hanisch, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
  • Anti-FAP antibodies and methods of use
    Patent number: 10253110
    Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: April 9, 2019
    Assignee: ROCHE GLYCART AG
    Inventors: Marina Bacac, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • MUTANT INTERLEUKIN-2 POLYPEPTIDES
    Publication number: 20190077881
    Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: November 21, 2018
    Publication date: March 14, 2019
    Applicant: Roche Glycart AG
    Inventors: Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • BISPECIFIC ANTIBODIES SPECIFIC FOR FAP AND DR5, ANTIBODIES SPECIFIC FOR DR5 AND METHODS OF USE
    Publication number: 20190062453
    Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: March 6, 2018
    Publication date: February 28, 2019
    Applicant: Roche Glycart AG
    Inventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, lnja Waldhauer, Huisheng Wang, Barbara Weiser
  • Immunoconjugates
    Patent number: 10202464
    Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: February 12, 2019
    Assignee: ROCHE GLYCART AG
    Inventors: Oliver Ast, Peter Bruenker, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana
  • ASPGR ANTIBODIES AND USES THEREOF
    Publication number: 20190031760
    Abstract: The present invention generally relates to antibodies specific for asialoglycoprotein receptor (ASGPR) and their use for selectively delivering effector moieties that influence cellular activity. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies of the invention, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: September 14, 2018
    Publication date: January 31, 2019
    Applicant: ROCHE GLYCART AG
    Inventors: Thomas HOFER, Changhua Ji, Ekkehard Moessner, Pablo Umana
  • T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES
    Publication number: 20190031784
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: June 22, 2018
    Publication date: January 31, 2019
    Inventors: Marina Bacac, Peter Bruenker, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
  • Mutant interleukin-2 polypeptides
    Patent number: 10184009
    Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: January 22, 2019
    Assignee: ROCHE GLYCART AG
    Inventors: Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • TRIMERIC COSTIMULATORY TNF FAMILY LIGAND-CONTAINING ANTIGEN BINDING MOLECULES
    Publication number: 20190016771
    Abstract: The invention relates to novel trimeric costimulatory TNF family ligand-containing antigen binding molecules comprising three fusion polypeptides, each of the three fusion polypeptides comprising (a) an ectodomain of a costimulatory TNF family ligand selected from the group consisting of 4-1BBL, OX40L and GITRL or fragments thereof, (b) a trimerization domain, in particular a trimerization domain derived from human cartilage matrix protein (huCMP) of SEQ ID NO:1, and (c) a moiety capable of specific binding to a target cell antigen, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 17, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria AMANN, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20190002564
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 18, 2018
    Publication date: January 3, 2019
    Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20190002565
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 18, 2018
    Publication date: January 3, 2019
    Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane JAEGER, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • Bispecific T cell activating antigen binding molecules
    Patent number: 10155815
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: December 18, 2018
    Assignee: Roche Glycart AG
    Inventors: Marina Bacac, Thomas Hofer, Ralf Hosse, Christiane Neumann, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE
    Publication number: 20180344848
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD79b antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD79b antibody-drug conjugate.
    Type: Application
    Filed: August 10, 2018
    Publication date: December 6, 2018
    Applicants: Hoffmann-La Roche Inc., Genentech, Inc.
    Inventors: Christian Klein, Sabine Lang, Pablo Umana, Andrew Polson
  • NOVEL BISPECIFIC ANTIGEN BINDING MOLECULES CAPABLE OF SPECIFIC BINDING TO CD40 AND TO FAP
    Publication number: 20180340030
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: April 3, 2018
    Publication date: November 29, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Alexander BUJOTZEK, Harald DUERR, Guy GEORGES, Christian KLEIN, Stephane LECLAIR, Moritz RAPP, Eva Carina SUM, Christine TRUMPFHELLER, Pablo UMAÑA